The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma

The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma

Multiple myeloma is a malignancy of terminally differentiated plasma cells, characterized by an extreme genetic heterogeneity that poses great challenges for its successful treatment. Due to antibody overproduction, MM cells depend on the precise regulation of the protein degradation systems. Despit...

Full description

Bibliographic Details
Main Authors:	Tina Paradzik, Cecilia Bandini, Elisabetta Mereu, Maria Labrador, Elisa Taiana, Nicola Amodio, Antonino Neri, Roberto Piva
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	Cancers
Subjects:	multiple myeloma proteasome inhibitors drug resistance combinatorial treatment synthetic lethality
Online Access:	https://www.mdpi.com/2072-6694/13/6/1235

Similar Items

Proteasome inhibitors: A rational for clinical use in the treatment of multiple myeloma
by: Petković Ivan, et al.
Published: (2016-01-01)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
by: Diego Acosta-Alvear, et al.
Published: (2015-09-01)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
by: Noah M. Merin, et al.
Published: (2014-12-01)

Proteasome Inhibitors for the Treatment of Multiple Myeloma
by: Shigeki Ito
Published: (2020-01-01)

New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)

The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells
by: Naama Shalem-Cohavi, et al.
Published: (2019-05-01)

Iron Causes Lipid Oxidation and Inhibits Proteasome Function in Multiple Myeloma Cells: A Proof of Concept for Novel Combination Therapies
by: Jessica Bordini, et al.
Published: (2020-04-01)

Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK
by: Appelmann, I., et al.
Published: (2022)

Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma
by: John H. Chen, et al.
Published: (2017-06-01)

Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma
by: Dominika Fassmannová, et al.
Published: (2020-04-01)

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma
by: Ya-Wei Qiang, et al.
Published: (2018-07-01)

The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma
by: Laure Maneix, et al.
Published: (2021-02-01)

Identification of Long Non‐Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors
by: Ehsan Malek, et al.
Published: (2016-10-01)

Unexpected hope for a multiple myeloma patient
by: Minodora Cezarina Onisâi, et al.
Published: (2020-10-01)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure
by: David S. Pitcher, et al.
Published: (2015-07-01)

Expression of E3 Ubiquitin Ligases in Multiple Myeloma Patients after Treatment with the Proteasome Inhibitor Bortezomib
by: James Joseph Driscoll
Published: (2015-01-01)

S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma
by: Minxia Liu, et al.
Published: (2021-08-01)

ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF‐κB in multiple myeloma
by: Jifeng Jiang, et al.
Published: (2020-10-01)

Genomic Instability in Multiple Myeloma: A “Non-Coding RNA” Perspective
by: Elisa Taiana, et al.
Published: (2021-04-01)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
by: Muz B, et al.
Published: (2016-01-01)

Proteasome inhibitors: situation and prospects (literature review and own data)
by: A. A. Rukavitsyn, et al.
Published: (2016-10-01)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
by: Mohan M, et al.
Published: (2017-03-01)

Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
by: Xiaoyan Han, et al.
Published: (2021-06-01)

Exploring EZH2-Proteasome Dual-Targeting Drug Discovery through a Computational Strategy to Fight Multiple Myeloma
by: Filipe G. A. Estrada, et al.
Published: (2021-09-01)

Synthesis and Evaluation of Aza-Peptide Carbonyl Derivatives: A New Class of Proteasome Inhibitors
by: Lotti Diaz, Leilani Milagros
Published: (2019)

Corrigendum: Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China
by: Xiaoyan Han, et al.
Published: (2021-09-01)

<i>Nocardia farcinica</i> Brain Abscess in a Multiple Myeloma Patient Treated with Proteasome Inhibitor: A Case Report and Review of the Literature
by: Nengwen Xu, et al.
Published: (2021-09-01)

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer
by: Laia Castells-Roca, et al.
Published: (2021-03-01)

The proteasome and the degradation of oxidized proteins: Part I—structure of proteasomes
by: Tobias Jung, et al.
Published: (2013-01-01)

Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity
by: Carol Chen-Scarabelli, et al.
Published: (2017-07-01)

New Possibilities of Treatment for Relapsed/Refractory Multiple Myeloma: A Literature Review
by: OM Votyakova
Published: (2017-10-01)

The regional register of multiple myeloma: significance in the era of new drugs
by: K D Kaplanov, et al.
Published: (2016-12-01)

Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma
by: Seiichi Okabe, et al.
Published: (2021-03-01)

Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series
by: Bonnie A. Sklar, et al.
Published: (2019-05-01)

Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer
by: Laura L. Thompson, et al.
Published: (2017-11-01)

Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death
by: Mélody Caillot, et al.
Published: (2021-05-01)

Latest Development in Multiple Myeloma
by: Yoichi Imai
Published: (2020-09-01)

Comorbidities in patients with multiple myeloma
by: L. P. Kuznetsova, et al.
Published: (2019-08-01)

New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
by: Richardson PG, et al.
Published: (2017-08-01)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
by: Arnold Méndez-Toro, et al.
Published: (2020-09-01)